|
Antiviral and Preclinical Profiles of HCV NS5A Inhibitors IDX380 and IDX719
|
|
|
Reported by Jules Levin
Presented at the 18th International Symposium on Hepatitis C Virus and Related Viruses; Seattle; September 8-12, 2011
John P. Bilello, Cyril B. Dousson, Massimiliano La Colla, Christopher Chapron, Sanjeev Bhadresa, Michelle Camire, Ilaria Serra, Joshua M. Gillum, Lisa B. Lallos, Joseph F. McCarville, Xin-Ru Pan-Zhou, Marita Larsson Cohen and David N. Standring
Idenix Pharmaceuticals, Inc., Cambridge, MA, USA and Montpellier, France
![HCV1.gif](../images/020113/020113-5/HCV1.gif)
![HCV2.gif](../images/020113/020113-5/HCV2.gif)
![HCV3.gif](../images/020113/020113-5/HCV3.gif)
![HCV4.gif](../images/020113/020113-5/HCV4.gif)
![HCV5.gif](../images/020113/020113-5/HCV5.gif)
![HCV6.gif](../images/020113/020113-5/HCV6.gif)
|
|
|
|
|
|
|